Affini-T Therapeutics
PrivateLast Round
VC Round
Oct 15, 2024
Total Funding Raised
$180M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Affini-T Therapeutics operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a VC Round in October 2024.
Affini-T Therapeutics is a biotechnology company that develops precision-engineered T-cell receptor (TCR) therapies targeting oncogenic driver mutations to treat solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Affini-T Therapeutics Comparables
Compare Affini-T Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoVanta Therapeutics | 84% | |
| Hula Therapeutics | 83% | |
| T-knife Therapeutics | 81% |
For institutional investors. Book with your work email.
Affini-T Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 15, 2024 | ||||
| Series B Extension | Aug 1, 2024 | ||||
| Series A | Mar 22, 2022 | ||||
| Seed | Dec 24, 2020 |
For institutional investors. Book with your work email.
Affini-T Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series A |
| Vida Ventures | Series A |
| Parker Institute for Cancer Immunotherapy | Series A |
| Catalio Capital Management | Series A |
| Humboldt Fund | Series A |
| Alexandria Venture Investments | Series A |
| Leaps by Bayer | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 39% MoM.
- Jan 9, 2025
Will present at the 43rd Annual J.P. Morgan Healthcare Conference.
For institutional investors. Book with your work email.
Affini-T Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Affini-T Therapeutics's valuation, stock price, and market status.
Is Affini-T Therapeutics a public or private company?
Affini-T Therapeutics is a private company.
What is the current stock price of Affini-T Therapeutics?
Affini-T Therapeutics is a private company, so its shares have no public market price. Caplight tracks Affini-T Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Affini-T Therapeutics worth (valuation)?
Valuation information for Affini-T Therapeutics is not publicly available.
Can I buy Affini-T Therapeutics stock?
Affini-T Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Affini-T Therapeutics's last funding round?
Affini-T Therapeutics's most recent funding round was VC Round on October 15, 2024.
Who are the main investors in Affini-T Therapeutics?
Key investors in Affini-T Therapeutics include Vida Ventures, Leaps by Bayer.
Will Affini-T Therapeutics IPO soon?
No public IPO plans have been announced for Affini-T Therapeutics.
How can I track Affini-T Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Affini-T Therapeutics's shares on secondary markets.